Damora Therapeutics, Inc. (DMRA) Live Share Price, Invest From India

Damora Therapeutics, Inc. Stock Performance

as on April 28, 2026 at 6:59 am IST

Day's Low
Day's High
$24.40
Day's Price Range
$26.23
$25.54
4.46%
Downside
2.70%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$25.54
100.00%
Downside
-100.00%
Upside

Damora Therapeutics, Inc. share price movements today

Previous Close: $24.75
Open: $24.49
Volume: 351.8K
Day's Low - High: $24.40 - $26.23

Damora Therapeutics, Inc. Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Damora Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Damora Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.5B

EPS (TTM)

-2.35

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-163.80%

Damora Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Damora Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Damora Therapeutics, Inc.	NA	$1.5B	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.8B	114.94%	131.7	8.45%
Vertex Pharmaceuticals Inc	BUY	$109.5B	99.55%	28.1	32.94%
BeiGene, Ltd.	NA	$33.4B	NA	121.78	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.0B	52.62%	17.95	31.41%

Damora Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Damora Therapeutics, Inc. Stock has decreased by -51% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 29, 2026 to April 28, 2026

Change:-51% versus previous 30 day period

Damora Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0
Operating Income	-3	-2	-2	-3	-3	-201
EBITDA	-3	-2	-2	-3	-3	-201
Interest Expense	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0
Income Before Tax	-3	-6	-2	-3	-3	-200
Income Tax Expense	0	0	0	0	-	0
Net Income	-3	-6	-2	-3	-3	-200
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Damora Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-
Gross Profit	0	0	0	0	0
Operating Income	-52	-61	-36	-16	-210
EBITDA	-51	-60	-35	-16	-210
Interest Expense	-	-	-	-	-
Depreciation	0	0	0	0	0
Income Before Tax	-51	-61	-38	-21	-209
Income Tax Expense	-	-	-	0	0
Net Income	-51	-61	-38	-21	-209
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Damora Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-6	-5	-5	-3	-6	-2	-3	-3	-200
Operating Cash Flow	-11	-5	-4	-3	-4	-2	-2	-2	0
Investing Cash Flow	9	5	6	-	-	-	-	-	-17
Financing Cash Flow	-	-	-	-	-	-	-	-	266
Change in Cash	-1	0	1	-3	-4	-2	-2	-2	250

Damora Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-36	-34	-51	-61	-38	-21	-209
Operating Cash Flow	-19	-38	-52	-42	-36	-18	-6
Investing Cash Flow	0	-	-48	12	22	11	-17
Financing Cash Flow	-	187	-	0	2	-	266
Change in Cash	-19	152	-101	-29	-11	-7	243

Insights on Damora Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, DMRA stock has moved up by 256.1%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DMRA has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 3 years, Damora Therapeutics Inc has experienced a drawdown of -42.0%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 34.8%

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Organisation	Damora Therapeutics, Inc.
Headquarters	Building 23, Waltham, MA, United States, 02453
Industry	Biotechnology
CEO	Ms. Jennifer A. Jarrett M.B.A.
E-voting on shares	Click here to vote

Key Management of Damora Therapeutics, Inc.

Name	Title
Dr. Hakon Leffler M.D., Ph.D.	Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.	Co-Founder
Mr. Sherwin Sattarzadeh	Chief Operating Officer
Dr. Becker Hewes M.D.	Chief Medical Officer
Ms. Lori C. Firmani	Chief Financial Officer
Mr. Garrett Winslow Esq.	Senior VP, General Counsel & Corporate Secretary
Ms. Jennifer A. Jarrett M.B.A.	CEO, President & Director
Mr. Ulf J. Nilsson Ph.D.	Co-Founder

FAQs

What is Damora Therapeutics, Inc. share price today?

Damora Therapeutics, Inc. share price today is $25.54 as on April 28, 2026 at 1:29 am IST at the close of the market. Damora Therapeutics, Inc. share today touched a day high of $26.23 and a low of $24.4.

What is the 52 week high and 52 week low for Damora Therapeutics, Inc. share?

Damora Therapeutics, Inc. share touched a 52 week high of $ on January 1, 1970 and a 52 week low of $ on January 1, 1970. Damora Therapeutics, Inc. stock price today i.e. April 28, 2026 at 1:29 am IST is closed at $25.54,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Damora Therapeutics, Inc.'s market capitalisation today?

Damora Therapeutics, Inc. market capitalisation is $0.00T as on April 28, 2026 at 1:29 am IST.

How to invest in Damora Therapeutics, Inc. Stock (DMRA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Damora Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Damora Therapeutics, Inc. Shares that will get you 0.0587 shares as per Damora Therapeutics, Inc. share price of $25.54 per share as on April 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Damora Therapeutics, Inc. Stock (DMRA) from India?

Indian investors can start investing in Damora Therapeutics, Inc. (DMRA) shares with as little as ₹94.52 or $1 (as of April 28, 2026 at 5:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹945.20 in Damora Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on April 28, 2026 at 5:37 pm IST). Based on Damora Therapeutics, Inc. share’s latest price of $25.54 as on April 28, 2026 at 1:29 am IST, you will get 0.3915 shares of Damora Therapeutics, Inc.. Learn more about fractional shares .